Many liver diseases are associated with endocrine disorders, including nonalcoholic fatty liver disease (NAFLD), autoimmune hepatitis and primary biliary cirrhosis. NAFLD is the most common liver disorder worldwide and its rising prevalence mirrors that of obesity and type 2 diabetes. Thyroid disorders are often associated with hepatic alterations. Chronic liver disease can impair menstruation and fertility. In addition, patients with diabetes have a higher prevalence of significant liver fibrosis and enhanced risk of disease progression to cirrhosis and hepatocellular carcinoma. Management of these disorders should consider the relationship between the liver and the endocrine system, in order to address all manifestations and complications.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Liver Disorders Content
Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls
touchREVIEWS in Endocrinology. 2021;17(1):Online ahead of journal publication
Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease globally; it is histologically classified into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH).1 NAFL is characterized by the presence of >5% of hepatic steatosis without evidence of hepatocellular injury in the form of hepatocyte ballooning. NASH is the advanced stage of […]
The Prevalence and Predictors of Non-alcoholic Fatty Liver Disease in Morbidly Obese Women – A Cross-sectional Study from Southern India
European Endocrinology. 2020;16(2):152–5 DOI: https://doi.org/10.17925/EE.2020.16.2.152
The prevalence of obesity is rapidly increasing across the world. In India, about 12.6% women and 9.3% men are obese, amounting to more than a 100 million population.1 Obesity, which was earlier considered to be a growing problem only in metropolitan cities, is now noted to be just as prevalent in smaller semi-urban towns.2 It is not […]
A Novel Small Molecule Drug Derived from Methimazole (Phenylmethimazole) that Targets Aberrant Toll-like Receptor Expression and Signaling for the Potential Prevention or Treatment of Diabetes Mellitus and Non-alcoholic Fatty Liver Disease
US Endocrinology, 2015;11(1):17–23 DOI: http://doi.org/10.17925/USE.2015.11.1.17
There are two major forms of diabetes mellitus, type 1 (T1DM) and type 2 (T2DM), with the latter being the most common form, accounting for over 90 % of cases.1 Further, with the epidemic of obesity, T2DM can occur at any age, including children and adolescents,1 affecting nearly 30 million in the US and 400 […]
The Role of Visceral Adipose Tissue in the Pathogenesis of Non-alcoholic Fatty Liver Disease
European Endocrinology, 2011;7(2):96-103 DOI: http://doi.org/10.17925/EE.2011.07.02.96
Non-alcoholic fatty liver disease (NAFLD), actually the most common cause of chronic liver injury, comprises a disease spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), advanced fibrosis and cirrhosis.1,2 NAFLD is defined as an accumulation of fat, mainly triglycerides (TG), in hepatocytes exceeding 5–10 % of the liver weight and this in the absence […]
Non-alcoholic Fatty Liver Disease in Children
European Endocrinology, 2010; 6:60-3; DOI: http://doi.org/10.17925/EE.2010.06.00.60
Since non-alcoholic fatty liver disease (NAFLD) was first described in children in the early 1980s by Moran and colleagues,1 a number of case series have been reported. Awareness of the disease has been growing among healthcare providers in the last few years, and nowadays NAFLD represents the most common cause of chronic liver disease in […]
Non-alcoholic Fatty Liver Disease and Type 2 Diabetes
European Endocrinology, 2008; 4(2):70-3; DOI: http://doi.org/10.17925/EE.2008.04.02.70
The prevalence of NAFLD has increased in parallel with the epidemics of obesity and type 2 diabetes, which are risk factors for NAFLD.3,6 Whereas the association of type 2 diabetes with microvascular complications and macrovascular disease is well established, the association of type 2 diabetes with NAFLD is more recently recognised and probably less well-known […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!